<SEC-DOCUMENT>0001628280-23-035948.txt : 20231101
<SEC-HEADER>0001628280-23-035948.hdr.sgml : 20231101
<ACCEPTANCE-DATETIME>20231101160240
ACCESSION NUMBER:		0001628280-23-035948
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20231101
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20231101
DATE AS OF CHANGE:		20231101

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			SANGAMO THERAPEUTICS, INC
		CENTRAL INDEX KEY:			0001001233
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				680359556
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30171
		FILM NUMBER:		231368113

	BUSINESS ADDRESS:	
		STREET 1:		7000 MARINA BLVD
		CITY:			BRISBANE
		STATE:			CA
		ZIP:			94005
		BUSINESS PHONE:		5109706000

	MAIL ADDRESS:	
		STREET 1:		7000 MARINA BLVD
		CITY:			BRISBANE
		STATE:			CA
		ZIP:			94005

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SANGAMO BIOSCIENCES INC
		DATE OF NAME CHANGE:	20000208
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>sgmo-20231101.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with the Workiva Platform--><!--Copyright 2023 Workiva--><!--r:82291fdc-e6dc-49f6-ab3d-90cc9a7a8a5e,g:273cb21f-642a-4392-81de-bd975c1f1169,d:b48c9b19fb8f49989e3d29b903bdfed4--><html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>sgmo-20231101</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-21">November 1, 2023</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-22">0001001233</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" id="f-23">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="sgmo-20231101.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-01</xbrli:startDate><xbrli:endDate>2023-11-01</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ib48c9b19fb8f49989e3d29b903bdfed4_1"></div><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:100%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:100%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Washington, D.C. 20549</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:100%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">8-K</ix:nonNumeric> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">CURRENT REPORT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Pursuant to Section&#160;13 or 15(d)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">of the Securities Exchange Act of 1934</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Date of Report (Date of earliest event reported): <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-2">November&#160;1, 2023</ix:nonNumeric></span></div><div style="margin-top:10pt;text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-3">SANGAMO THERAPEUTICS, INC.</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Exact name of registrant as specified in its charter)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:30.571%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.292%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.571%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.292%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.574%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-4">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">000-30171</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-6">68-0359556</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or other jurisdiction of<br/>incorporation)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Commission<br/>File Number)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(IRS Employer<br/>ID Number)</span></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-7">7000 Marina Blvd.</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-8">Brisbane</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-9">California</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-10">94005</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Address of principal executive offices) (Zip Code)</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-11">510</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-12">970-6000</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Registrant&#8217;s telephone number, including area code)&#160;</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Not Applicable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Former Name or Former Address, if Changed Since Last Report)&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:5.781%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:92.019%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="f-13">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:5.781%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:92.019%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="f-14">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.614%"><tr><td style="width:1.0%"></td><td style="width:6.086%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:91.714%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="f-15">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"><tr><td style="width:1.0%"></td><td style="width:6.119%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:91.681%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="f-16">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Securities registered pursuant to Section&#160;12(b) of the Act:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:30.571%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.292%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.571%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.292%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.574%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-17">Common Stock, $0.01 par value per share</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-18">SGMO</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-19">Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#160;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;&#160;240.12b-2 of this chapter). </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging growth company&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="f-20">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div><div style="margin-top:10pt"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;2.02 Results of Operations and Financial Condition.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November&#160;1, 2023, Sangamo Therapeutics, Inc. (&#8220;Sangamo&#8221;) issued a press release announcing its financial results for the quarter ended September 30, 2023 (the &#8220;Press Release&#8221;).</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A copy of the Press Release is furnished hereto as Exhibit 99.1 and is incorporated by reference herein. The information contained in this Item 2.02 and in the Press Release furnished as Exhibit 99.1 to this Current Report on Form 8-K shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 2.02 and in the Press Release furnished as Exhibit 99.1 to this Current Report on Form 8-K shall not be incorporated by reference into any filing with the Securities and Exchange Commission (the &#8220;SEC&#8221;) made by Sangamo whether made before or after the date hereof, regardless of any general incorporation language in such filing.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;9.01 Financial Statements and Exhibits.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Exhibits</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.543%"><tr><td style="width:1.0%"></td><td style="width:12.170%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.165%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:74.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.901%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.693%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit<br/>No.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit-991110123.htm">Press Release regarding financial results dated </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit-991110123.htm">November 1</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit-991110123.htm">, 2023</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.139%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.578%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.478%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.139%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.990%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SANGAMO THERAPEUTICS, INC.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated: November 1, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ SCOTT B. WILLOUGHBY</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Scott B. Willoughby</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President, General Counsel and Corporate Secretary</span></td></tr></table></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exhibit-991110123.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i173f084bc12d4669ac067ef5853d8a2c_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="padding-left:432pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 99.1</font></div><div><img alt="logoa.gif" src="logoa.gif" style="height:100px;margin-bottom:5pt;vertical-align:text-bottom;width:300px"></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SANGAMO THERAPEUTICS ANNOUNCES STRATEGIC UPDATE AND REPORTS </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">THIRD QUARTER 2023 FINANCIAL RESULTS</font></div><div><font><br></font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Announced additional progress towards strategic transformation into neurology-focused genomic medicine company.</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Focusing resources on proprietary epigenetic regulation therapies treating neurological diseases and novel AAV capsid delivery technologies.</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Dosed a total of 25 patients in Phase 1&#47;2 STAAR study in Fabry disease, with promising clinical data continuing to emerge. Deferring additional investments in Phase 3 planning until collaboration partner or Phase 3 trial funding secured. </font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Actively seeking collaboration partners or direct investors in CAR-Treg cell therapy programs. Deferring new investments until collaboration partner or external investment is secured.</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Announced planned shutdown of Brisbane headquarters, restructuring of operations, and US workforce reduction of approximately 40%. </font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Cost savings expected from the restructuring, workforce reduction and other potential cost reductions anticipated to reduce annual operating expenses by approximately 50%.</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Conference call and webcast scheduled for Thursday, November 2, 8&#58;30 a.m. Eastern Time.</font></div><div><font><br></font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Brisbane, California, November 1, 2023</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Sangamo Therapeutics, Inc. (Nasdaq&#58; SGMO), a genomic medicines company, today announced recent business highlights, including progress on its strategic transformation and a corresponding restructuring of operations and workforce reduction, and reported third quarter 2023 financial results.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;In 2020, we shared our refreshed company strategy which aims to both maximize the potential of our proprietary genomic editing and delivery technology, and to focus on areas where we believe we can apply that technology to be either first-in-class or best-in-class. The process of streamlining Sangamo&#8217;s pipeline has been accelerated within today&#8217;s challenging economic environment and we have had to make difficult decisions to defer further investments and seek collaboration partners or direct investment in both our Fabry gene therapy and CAR-Treg cell therapy programs,&#8221; said Sandy Macrae, Chief Executive Officer of Sangamo. &#8220;As we work to unlock value in our clinical programs that is not currently reflected as part of Sangamo, we plan to do everything in our power to get these important assets into the hands of parties with the means to advance them towards patients. At the same time, we will continue to progress our promising epigenetic regulation programs for neurological diseases and hope to soon share a breakthrough in our capsid delivery capabilities, which we believe could open the door for many other high-value and unmet diseases to be addressed with our editing capabilities. We continue to seek ways to raise additional capital to strengthen our financial foundation.&#8221;</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The restructuring announced today represents a further step towards simplifying the Sangamo organization and focusing on our epigenetic regulation therapies treating neurological diseases and our novel AAV capsid delivery technologies. Sangamo is deferring new investments in its Fabry and CAR-Treg programs beyond what is currently committed and is actively seeking collaboration partners or direct investors in both. In addition, Sangamo expects to close its Brisbane, California facility in early 2024 to conserve cash resources, and will transition its headquarters to its Richmond, California facility as of January 1, 2024. As a result of this restructuring, Sangamo is reducing its US workforce by approximately 40%, or approximately 162 roles. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the restructuring, D. Mark McClung, Executive Vice President, Chief Operating Officer and Jason Fontenot, Senior Vice President, Chief Scientific Officer will be leaving the company on January 2, 2024. In the context of a streamlined and more focused organization, we are eliminating their roles. Until his departure, Mark will continue to lead our search for partners and investors in our Fabry and CAR-Treg programs. Amy Pooler, currently serving as Vice President, Neuroscience and Gregory Davis, currently serving as Vice President, Genome Engineering Design and Technology, have been appointed as Head of Research and Head of Technology, respectively, effective November 17, 2023.</font></div><div style="margin-top:6pt"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The restructuring and workforce reductions, in combination with other potential cost reductions, are anticipated to reduce our non-GAAP annual operating expenses from approximately $240 million-$260 million in 2023 to approximately $115 million-$135 million in 2024, a decrease of approximately 50%. Sangamo expects to incur approximately $8 million-$10 million in one-time restructuring costs in the fourth quarter of 2023. Sangamo believes its cash, cash equivalents, and marketable securities as of September 30, 2023, in combination with the cost savings expected from the restructuring, workforce reduction and other potential cost reductions, will be sufficient to fund its planned operations into the third quarter of 2024.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dr. Macrae continued&#58; &#8220;I am grateful to all our employees for their commitment to Sangamo&#8217;s mission and the patients we seek to serve, and have special appreciation to all those who are leaving for their important contributions. Additionally, I would like to personally thank Mark for the wisdom, candor and leadership he has brought to Sangamo. He has been a trusted colleague and will be greatly missed. I would also like to thank Jason for his dedication, passion and leadership. He leaves a strong scientific legacy for which we will always be grateful.&#8221;</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Business Highlights</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Program Highlights</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Neurology Epigenetic Regulation Programs &#8211; Progressed IND-enabling activities for Nav1.7&#59; presented updated preclinical data at Prion 2023&#59; presented preclinical data on zinc finger activators at the European Society of Gene and Cell Therapy (ESGCT)&#59; made significant progress in identifying new, potentially transformative AAV delivery capsids.</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Progressed IND enabling activities for the Nav1.7 program to treat chronic neuropathic pain. Continue to expect an IND submission for this program in 2024. </font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Presented data from the prion disease program at the Prion 2023 Conference in October 2023, showing in animal models that Sangamo&#8217;s zinc finger repressors significantly reduce expression of the prion protein in the brain, extend lifespan and limit the formation of toxic prion aggregates. </font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Presented an oral presentation at ESGCT in October 2023, showing that our zinc finger activators can be designed to restore normal gene and protein expression of SCN2A </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to potentially address neurodevelopmental disorders such as autism spectrum disorder and intellectual disability. </font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Presented data on Shank3 gene activation mediated by zinc finger transcriptional activators as a potential therapeutic approach for Phelan-McDermid Syndrome at ESGCT. </font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Continued to advance identification and selection of engineered AAV capsids for enhanced central nervous system delivery through both intrathecal and intravenous delivery. Anticipate sharing nonhuman primate data from our capsid development efforts in early 2024.</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fabry Disease &#8211; Dosed total of 25 patients in Phase 1&#47;2 STAAR study&#59; all patients dosed to date continue to demonstrate sustained, elevated &#945;-Gal A levels for up to three years for the longest treated patient&#59; received Regenerative Medicine Advanced Therapy (RMAT) Designation from U.S. FDA&#59; enrolled sufficient patients in the Phase 1&#47;2 study believed to provide a preliminary assessment of safety and efficacy&#59; deferring Phase 3 planning investments and actively seeking partners and investment.</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Dosed three additional patients in the dose expansion phase of the Phase 1&#47;2 STAAR study evaluating isaralgagene civaparvovec, our wholly owned gene therapy product for the treatment of Fabry disease, for a total of 25 patients dosed to date, including 14 at the planned Phase 3 dose of 5x10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> vg&#47;kg. </font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">All patients dosed to date continue to demonstrate sustained, elevated &#945;-Gal A levels, with 12 patients having achieved at least one year of follow-up and the longest treated patient having achieved three years of follow-up.</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">All 11 patients who were withdrawn from enzyme replacement therapy (ERT) remain off ERT, for up to 24 months for the longest withdrawn patient.</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Treated patients continue to report improvements in their quality of life, some even over and above the benefits they were experiencing on ERT.</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Received U.S. FDA RMAT designation for isaralgagene civaparvovec, which aims to expedite the review of new therapeutics that are intended to address an unmet need in patients with serious conditions. The U.S. FDA has previously granted isaralgagene civaparvovec both Orphan Drug and Fast Track Designations.</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Stopping further screening and enrollment in the Phase 1&#47;2 STAAR study, after successfully enrolling sufficient patients believed to provide a preliminary assessment of efficacy and safety in the Phase 1&#47;2 study.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Expect to complete dosing of the remaining enrolled patients in the first half of 2024.</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Anticipate presenting updated Phase 1&#47;2 clinical data at a medical meeting in early 2024.</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Deferring additional investments in Phase 3 planning until collaboration partnership or Phase 3 trial financing is secured.</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">CAR-Tregs &#8211; Received approval for accelerated dosing protocol for Phase 1&#47;2 STEADFAST study from European regulatory authorities&#59; dosed the first patient in the second dose cohort&#59; successfully manufactured product candidate for third and new fourth dose levels&#59; presented updated preclinical data at ESGCT&#59; seeking a collaboration partner or direct investment in CAR-Tregs. </font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Dosed the first patient in the second cohort of the Phase 1&#47;2 STEADFAST study evaluating TX200, our wholly owned autologous CAR-Treg cell therapy treating patients receiving an HLA-A2 mismatched kidney from a living donor.</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The product candidate continues to be generally well tolerated in all four patients dosed to date. </font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Received all necessary regulatory and ethics approvals for an accelerated dose escalation protocol from European regulatory authorities that could allow dosing to advance more quickly through the cohorts and which allows for a new and highest fourth dose cohort, compared to the three cohorts in the previously approved study protocol. The new, fourth cohort dose will be 18-fold higher than the first cohort starting dose.</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Completed manufacturing of the dose for the patient in the third cohort, who recently received a kidney transplant. Dosing of this fifth patient is expected in the fourth quarter of 2023, pending approval from the Safety Monitoring Committee.</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Completed manufacturing of the dose for the first patient in the fourth and highest dose cohort, who recently received a kidney transplant. Dosing of this sixth patient is expected in January 2024, pending approval from the Safety Monitoring Committee &#8211; which would accelerate dosing plans by 18 months compared to the previously approved study protocol.</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Presented preclinical data at ESGCT demonstrating the potential of autologous MOG-CAR-Tregs to provide a long-lasting treatment option for multiple sclerosis and updated animal model data demonstrating the promise of IL23R-CAR-Tregs in the potential treatment of Crohn&#8217;s disease. </font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Actively seeking a potential collaboration partner or direct external investment in the CAR-Treg cell therapy programs. Expect to provide an update on these efforts in the first quarter of 2024. </font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Deferring new investments until a collaboration partner or external investment is secured.</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Hemophilia A (Pfizer) &#8211; dosing complete in Phase 3 AFFINE trial&#59; pivotal data read-out expected in mid-2024&#59; BLA and MAA submissions anticipated in second half of 2024.</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Pfizer has advised us that dosing is complete in the Phase 3 AFFINE trial of giroctocogene fitelparvovec, an investigational gene therapy we are developing with Pfizer for patients with moderately severe to severe hemophilia A. </font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A pivotal readout is expected in mid-2024, with Pfizer anticipating BLA and MAA submissions in the second half of 2024 if the pivotal readout is supportive. </font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Expect to present updated data with Pfizer from the Phase 1&#47;2 ALTA study of giroctocogene fitelparvovec in an oral presentation at the 65</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> American Society for Hematology Annual Meeting and Exposition on December 11, 2023.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Third Quarter 2023 Financial Results</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated net loss for the third quarter ended September 30, 2023 was $104.2 million, or $0.59 per share, compared to a net loss of $53.2 million, or $0.34 per share, for the same period in 2022, primarily due to a non-cash charge relating to impairment of long-lived asset of $44.8 million, which was a result of continued decline in our stock price and related market capitalization, initiation of actions to seek external financing and reprioritize certain research and development programs, and continued decline in equity values in the biotechnology industry.</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenues</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues for the third quarter ended September 30, 2023 were $9.4 million, compared to $26.5 million for the same period in 2022. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease of $17.1 million in revenues was primarily attributed to a decrease of $9.6 million and $9.1 million in revenue relating to our collaboration agreements with Novartis and Biogen, respectively, due to the termination of these collaboration </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">agreements in June 2023, and a decrease of $1.4 million in revenue relating to our collaboration agreement with Kite, reflecting a reduction in collaboration activities during the quarter. These decreases were partially offset by an increase of $3.0 million in revenue relating to our other license agreements.</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">GAAP and Non-GAAP Operating Expenses</font></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.338%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.457%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In millions)</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br>September 30,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br>September 30,</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57.1&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.1&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183.4&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183.7&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.9&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.2&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.1&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.2&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of goodwill and indefinite-lived intangible assets</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89.5&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of long-lived assets</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.8&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.2&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115.8&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.3&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">386.2&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229.9&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of goodwill and indefinite-lived intangible assets</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(89.5)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of long-lived assets</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44.8)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65.2)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.2)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.8)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21.3)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23.4)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-GAAP operating expenses</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.8&#160;</font></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.5&#160;</font></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210.2&#160;</font></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206.5&#160;</font></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total operating expenses on a GAAP basis for the third quarter ended September 30, 2023 were $115.8 million, compared to $81.3 million for the same period in 2022. GAAP operating expenses for the third quarter ended September 30, 2023 included a non-cash charge relating to impairment of long-lived asset of $44.8 million, as described above. Non-GAAP operating expenses, which exclude impairment charges and stock-based compensation expense, for the third quarter ended September 30, 2023 were $64.8 million, compared to $73.5 million for the same period in 2022.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in total operating expenses on a non-GAAP basis was primarily attributable to lower compensation and other personnel costs mainly due to lower headcount as a result of restructuring of operations and corresponding reduction in workforce announced in April 2023, and decrease in manufacturing and lab supply expenses due to deferral and reprioritization of certain research and development programs. These decreases were partially offset by higher facilities and infrastructure related costs, and higher external expenses as we advance our clinical and preclinical pipeline.</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash, Cash Equivalents and Marketable Securities</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents and marketable securities as of September 30, 2023 were $132.1 million, compared to $307.5 million as of December 31, 2022. As of September 30, 2023, we have raised approximately $15.1 million in net proceeds under our at-the-market offering program since January 1, 2023. We believe that our available cash, cash equivalents and marketable securities as of September 30, 2023, in combination with the cost savings expected from the restructuring, workforce reduction and other potential cost reductions, will be sufficient to fund our planned operations into the third quarter of 2024.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Updated Financial Guidance for 2023</font></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">GAAP operating expenses, including impairment of goodwill, indefinite-lived intangible assets, and long-lived assets, and stock-based compensation expense, for the full year 2023 are now estimated to be in the range of approximately $422 million to $442 million, reflecting the additional non-cash impairment charges recorded in the third quarter. The previous GAAP operating expenses guidance provided on August 8, 2023 was in the range of approximately $378 million to $398 million.</font></div><div style="margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We continue to estimate non-GAAP operating expenses to be in the range of approximately $240 million to $260 million, which remains unchanged from the last update on April 26, 2023. Estimated non-GAAP operating expenses exclude impairment of goodwill of $38.1 million, impairment of indefinite-lived intangible assets of $51.3 million, impairment of long-lived assets of $65.2 million, and stock-based compensation expense of $28.0 million.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Upcoming Events</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sangamo plans to participate in the following events&#58;</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investor Conferences</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Truist Securities BioPharma Symposium, November 8-9, 2023</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Jefferies London Healthcare Conference, November 14-16, 2023</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">EvercoreISI HealthCONx, November 28-30, 2023</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Access links for available webcasts for these investor conferences will be available on the Sangamo website in the Investors and Media section under</font><font style="color:#0a2299;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Events</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Available materials will be found on the Sangamo website after the event under</font><font style="color:#0a2299;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Presentations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Conference Call to Discuss Third Quarter 2023 Results</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Sangamo management team will discuss these results on a conference call tomorrow, Thursday, November 2, 2023, at 8&#58;30&#160;a.m. Eastern Time. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Participants should register for, and access, the call using </font><font style="color:#0a2299;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">this link</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. While not required, it is recommended you join 10 minutes prior to the event start. Once registered, participants will be given the option to either dial into the call with the number and unique passcode provided or to use the dial-out option to connect their phone instantly. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An updated corporate presentation is available in the Investors and Media section under</font><font style="color:#0a2299;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Presentations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The link to access the live webcast can also be found on the Sangamo website in the Investors and Media section under</font><font style="color:#0a2299;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Events</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. A replay will be available following the conference call, accessible at the same link.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">About Sangamo Therapeutics</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sangamo Therapeutics is a clinical-stage biopharmaceutical company with a robust genomic medicines pipeline. Using ground-breaking science, including our proprietary zinc finger genome engineering technology and manufacturing expertise, Sangamo aims to create new genomic medicines for patients suffering from diseases for which existing treatment options are inadequate or currently don&#8217;t exist. To learn more, visit www.sangamo.com and connect with us on LinkedIn and Twitter.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Forward-Looking Statements </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">This press release contains forward-looking statements regarding our current expectations. These forward-looking statements include, without limitation, statements relating to&#58; the therapeutic and commercial potential of our product candidates, the anticipated plans and timelines of Sangamo and our collaborators for screening, enrolling and dosing patients in and conducting our ongoing and potential future clinical trials and presenting clinical data from our clinical trials, including expectations regarding the conclusion of dosing in our Phase 1&#47;2 STAAR study, preparations and plans for patient dosing in the STEADFAST study, the potential for acceleration of the study timeline and the availability of data therefrom, the anticipated advancement of our product candidates to late-stage development, including Sangamo&#8217;s plans to seek a potential partner or additional financing to proceed with potential future Phase 3 trials of isaralgagene civaparvovec and the timing thereof, the timeline to present data from the Phase 3 AFFINE trial and to make BLA and MAA submissions for giroctocogene fitelparvovec, expectations regarding advancement of our preclinical neurology programs, including announcement of data from, and anticipated IND submissions related to, such programs, plans to seek a partner for or investor in our CAR-Treg program, expectations concerning our strategic prioritization and restructuring, including plans to close our Brisbane facility and the expected charges and cost savings associated with such restructuring, future potential cost reductions, our expected cash runway, our 2023 financial guidance related to GAAP and non-GAAP total operating expenses, impairments and stock-based compensation, our plans to participate in industry and investor conferences, and other statements that are not historical fact. These statements are not guarantees of future performance and are subject to certain risks and uncertainties that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties related to Sangamo&#8217;s ability to execute its strategic prioritization and restructuring as currently contemplated&#59; the actual charges associated with the restructuring being higher than anticipated or changes to the assumptions on which the estimated charges associated with the restructuring are based&#59; Sangamo&#8217;s ability to achieve projected cost savings in connection with the restructuring and to further reduce operating expenses&#59; unintended consequences from the restructuring that impact Sangamo&#8217;s business&#59; our lack of capital resources to fully develop, obtain regulatory approval for and commercialize our product candidates, including our ability to secure the funding required to initiate a potential Phase 3 trial of isaralgagene civaparvovec in a timely manner or at all&#59; our need for substantial additional funding to execute our operating plan and to continue to operate as a going concern&#59; the potential of our preclinical programs utilizing zinc finger technology to address neurological health disorders&#59; the effects of macroeconomic factors or financial challenges, including as a result of the ongoing overseas conflict, current or potential future bank failures, inflation and rising interest rates, on the global business environment, healthcare systems and business and operations of Sangamo and our collaborators, including the initiation and operation of clinical trials&#59; the research and development process, including the enrollment, operation and results of clinical trials and the presentation of clinical data&#59; the impacts of clinical trial delays, pauses and holds on clinical trial timelines and commercialization of product candidates&#59; the uncertain timing and unpredictable nature of clinical trial results, including the risk that therapeutic effects in the Phase 3 AFFINE trial will not be durable in patients as well as the risk that the therapeutic effects observed in the latest preliminary clinical data from the Phase 1&#47;2 STAAR study will not be durable in patients and that final clinical trial data from the study will not validate the safety and efficacy of isaralgagene civaparvovec, and that the </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">patients withdrawn from ERT will remain off ERT&#59; the unpredictable regulatory approval process for product candidates across multiple regulatory authorities&#59; reliance on results of early clinical trials, which results are not necessarily predictive of future clinical trial results, including the results of any Phase 3 trial of our product candidates&#59; the potential for technological developments that obviate technologies used by Sangamo&#59; our reliance on collaborators and our potential inability to secure additional collaborations, and our ability to achieve expected future financial performance.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">There can be no assurance that we and our collaborators will be able to develop commercially viable products. Actual results may differ materially from those projected in these forward-looking statements due to the risks and uncertainties described above and other risks and uncertainties that exist in the operations and business environments of Sangamo and our collaborators. These risks and uncertainties are described more fully in our Securities and Exchange Commission, or SEC, filings and reports, including in our Annual Report on Form 10-K for the year ended December 31, 2022, as supplemented by our Quarterly Report on Form 10-Q for the quarter ended September 30, 2023 to be filed with the SEC, and future filings and reports that Sangamo makes from time to time with the SEC. Forward-looking statements contained in this announcement are made as of this date, and we undertake no duty to update such information except as required under applicable law.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Non-GAAP Financial Measures</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">To supplement our financial results and guidance presented in accordance with GAAP, we present non-GAAP operating expenses, which excludes stock-based compensation expense and impairment of goodwill, indefinite-lived intangible assets and long-lived assets from GAAP operating expenses. We believe that this non-GAAP financial measure, when considered together with our financial information prepared in accordance with GAAP, can enhance investors&#8217; and analysts&#8217; ability to meaningfully compare our results from period to period and to our forward-looking guidance, and to identify operating trends in our business. We have excluded stock-based compensation expense because it is a non-cash expense that may vary significantly from period to period as a result of changes not directly or immediately related to the operational performance for the periods presented, and we have excluded impairment of goodwill, indefinite-lived intangible assets and long-lived assets to facilitate a more meaningful evaluation of our current operating performance and comparisons to our operating performance in other periods. This non-GAAP financial measure is in addition to, not a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP. We encourage investors to carefully consider our results under GAAP, as well as our supplemental non-GAAP financial information, to more fully understand our business.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contact&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Investor Relations &#38; Media Inquiries </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Louise Wilkie&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ir&#64;sangamo.com </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">media&#64;sangamo.com </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-more-</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SELECTED CONSOLIDATED FINANCIAL DATA</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(unaudited&#59; in thousands, except per share data)</font></div><div><font><br></font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Statement of Operations Data&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br>September 30,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br>September 30,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,398&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,460&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174,190&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,069&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,089&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,116&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183,351&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183,719&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,918&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,238&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,068&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,239&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of goodwill and indefinite-lived intangible assets</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,485&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of long-lived assets</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,799&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,232&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,806&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,354&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">386,136&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229,958&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(106,408)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54,894)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(211,946)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(145,889)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest and other income, net</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,515&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,769&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,610&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,754&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(102,893)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53,125)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(202,336)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(140,135)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense (benefit)</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,270&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,800)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(104,163)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53,155)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(197,536)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(140,305)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted net loss per share</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.59)</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.34)</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.14)</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.93)</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used in computing basic and diluted net loss per share </font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177,171&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158,042&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173,375&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150,850&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance Sheet Data&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br>2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br>2022</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, and marketable securities</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132,111&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">307,477&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219,697&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">562,509&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134,922&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">294,958&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">###</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>sgmo-20231101.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:82291fdc-e6dc-49f6-ab3d-90cc9a7a8a5e,g:273cb21f-642a-4392-81de-bd975c1f1169-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:sgmo="http://www.sangamo.com/20231101" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.sangamo.com/20231101">
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sgmo-20231101_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sgmo-20231101_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPageCoverPage" roleURI="http://www.sangamo.com/role/CoverPageCoverPage">
        <link:definition>0000001 - Document - Cover Page Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>sgmo-20231101_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:82291fdc-e6dc-49f6-ab3d-90cc9a7a8a5e,g:273cb21f-642a-4392-81de-bd975c1f1169-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_SecurityExchangeName_62155be7-3404-4749-94ec-6b050da27d7b_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_1a661c1b-c906-40ec-b3ee-f2a6d49fee48_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_d9036ce1-fdaf-45ff-bef3-50aa532e7746_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_6303ef69-9c66-4a95-9445-4dd7c4761fbd_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_4daeeffb-d53e-4911-ad9c-a781f9f0dc90_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_d58b09a7-89c2-4c9e-85aa-88a65525fa3c_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_a40b2006-fba4-476d-91b8-35f4a7544423_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_c7db61b6-a574-4487-a181-c72ccef41788_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_ff31f034-94e8-40da-ba11-68c6fb890b5b_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_0c72edf3-f8c1-48f7-ae44-a9f182e94a2e_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover page.</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_96325067-2f2c-40fb-908f-4cd8760a8d6f_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_94732805-4fba-4013-8bee-12c182f53e36_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_fbd9ef53-c52d-4427-bf7d-18e3f5bfcb1f_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_7cb355a6-23f4-4d7c-b547-3a18580d48c0_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_1c08af1a-20b8-4126-9769-c11e64a682d4_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_7d696c8e-f9d1-4232-9d48-44d0d1af50a1_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_82dfaf6d-6739-4279-abaa-42d0ec17623a_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_e19dca91-faa8-437a-bd7a-c9a24fedf726_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_4bded209-3ef7-4ea5-9c51-c82a162b6c73_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_1e4384fa-3012-43de-bc12-2f41e40fbccc_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_0fd1fed2-4ced-46c8-9edc-40e94063824e_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_fbddac25-f6e1-4f40-a4ce-e2baf288928d_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_a03d9986-3015-4c51-a296-d83b8e7368fd_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>sgmo-20231101_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:82291fdc-e6dc-49f6-ab3d-90cc9a7a8a5e,g:273cb21f-642a-4392-81de-bd975c1f1169-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.sangamo.com/role/CoverPageCoverPage" xlink:type="simple" xlink:href="sgmo-20231101.xsd#CoverPageCoverPage"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/CoverPageCoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_0b74eae6-3cbc-44a3-8e34-31919da7f99a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_70320f7d-f391-4bc9-96af-0b97537d66c6" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0b74eae6-3cbc-44a3-8e34-31919da7f99a" xlink:to="loc_dei_DocumentType_70320f7d-f391-4bc9-96af-0b97537d66c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_786f65aa-1444-46a0-b0ec-996ac3766a81" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0b74eae6-3cbc-44a3-8e34-31919da7f99a" xlink:to="loc_dei_DocumentPeriodEndDate_786f65aa-1444-46a0-b0ec-996ac3766a81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_face5716-62c4-41f8-8b05-7a5e285d3c46" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0b74eae6-3cbc-44a3-8e34-31919da7f99a" xlink:to="loc_dei_EntityRegistrantName_face5716-62c4-41f8-8b05-7a5e285d3c46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_3259ccc1-6e3a-479b-8cc8-eacb0fddfe14" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0b74eae6-3cbc-44a3-8e34-31919da7f99a" xlink:to="loc_dei_EntityIncorporationStateCountryCode_3259ccc1-6e3a-479b-8cc8-eacb0fddfe14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_422b0c21-3999-4cc6-9a23-7e450b28ac12" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0b74eae6-3cbc-44a3-8e34-31919da7f99a" xlink:to="loc_dei_EntityFileNumber_422b0c21-3999-4cc6-9a23-7e450b28ac12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_355f99bf-b7df-4395-abb0-a57a78ea3daf" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0b74eae6-3cbc-44a3-8e34-31919da7f99a" xlink:to="loc_dei_EntityTaxIdentificationNumber_355f99bf-b7df-4395-abb0-a57a78ea3daf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_0df74154-35be-4524-809b-8ceec61a802e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0b74eae6-3cbc-44a3-8e34-31919da7f99a" xlink:to="loc_dei_EntityAddressAddressLine1_0df74154-35be-4524-809b-8ceec61a802e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_dc85d2e5-e7c1-4d35-b577-96db17545133" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0b74eae6-3cbc-44a3-8e34-31919da7f99a" xlink:to="loc_dei_EntityAddressCityOrTown_dc85d2e5-e7c1-4d35-b577-96db17545133" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_66fe7021-01b1-4955-9980-5a781e028d94" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0b74eae6-3cbc-44a3-8e34-31919da7f99a" xlink:to="loc_dei_EntityAddressStateOrProvince_66fe7021-01b1-4955-9980-5a781e028d94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_72c6d29a-453c-4d63-a235-f599c32b2f20" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0b74eae6-3cbc-44a3-8e34-31919da7f99a" xlink:to="loc_dei_EntityAddressPostalZipCode_72c6d29a-453c-4d63-a235-f599c32b2f20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_942df551-38a9-4a50-b115-77c2dd29f324" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0b74eae6-3cbc-44a3-8e34-31919da7f99a" xlink:to="loc_dei_CityAreaCode_942df551-38a9-4a50-b115-77c2dd29f324" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_dccc43c0-5821-4ab8-b67e-1c9c2ad1fc2d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0b74eae6-3cbc-44a3-8e34-31919da7f99a" xlink:to="loc_dei_LocalPhoneNumber_dccc43c0-5821-4ab8-b67e-1c9c2ad1fc2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_a9d398a0-f540-43f7-9972-4abf9602afba" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0b74eae6-3cbc-44a3-8e34-31919da7f99a" xlink:to="loc_dei_WrittenCommunications_a9d398a0-f540-43f7-9972-4abf9602afba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_94a75544-4dd0-4a08-a99f-c7df68600853" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0b74eae6-3cbc-44a3-8e34-31919da7f99a" xlink:to="loc_dei_SolicitingMaterial_94a75544-4dd0-4a08-a99f-c7df68600853" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_96f75bbc-edbf-4e98-bac3-dbf240103f6e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0b74eae6-3cbc-44a3-8e34-31919da7f99a" xlink:to="loc_dei_PreCommencementTenderOffer_96f75bbc-edbf-4e98-bac3-dbf240103f6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_6ac56ae1-b94c-4f15-baf6-e2f33e1af17b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0b74eae6-3cbc-44a3-8e34-31919da7f99a" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_6ac56ae1-b94c-4f15-baf6-e2f33e1af17b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_9dcf42e7-75ae-47c3-ad83-ee8ccbdc1676" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0b74eae6-3cbc-44a3-8e34-31919da7f99a" xlink:to="loc_dei_Security12bTitle_9dcf42e7-75ae-47c3-ad83-ee8ccbdc1676" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_c5b80cb1-553f-444b-aa11-50282b8dd173" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0b74eae6-3cbc-44a3-8e34-31919da7f99a" xlink:to="loc_dei_TradingSymbol_c5b80cb1-553f-444b-aa11-50282b8dd173" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_d3efb6c7-50c2-4e1d-8139-5d7eb1c1d4e9" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0b74eae6-3cbc-44a3-8e34-31919da7f99a" xlink:to="loc_dei_SecurityExchangeName_d3efb6c7-50c2-4e1d-8139-5d7eb1c1d4e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_7be63d79-1bd0-43fe-80f2-166ec2352cbf" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0b74eae6-3cbc-44a3-8e34-31919da7f99a" xlink:to="loc_dei_EntityEmergingGrowthCompany_7be63d79-1bd0-43fe-80f2-166ec2352cbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_a9aca591-9777-4154-b7cc-5e9dce46efcc" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0b74eae6-3cbc-44a3-8e34-31919da7f99a" xlink:to="loc_dei_AmendmentFlag_a9aca591-9777-4154-b7cc-5e9dce46efcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_95cf31d8-5eca-4107-8cb9-13d1d4f38db7" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0b74eae6-3cbc-44a3-8e34-31919da7f99a" xlink:to="loc_dei_EntityCentralIndexKey_95cf31d8-5eca-4107-8cb9-13d1d4f38db7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>logoa.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logoa.gif
M1TE&.#EA@ -# 7   "'_"TY%5%-#05!%,BXP P$!   A^00      "P
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MQ"$' ;-E-79&/E157&_%98\ENQCT!2N% -OJI%]7 A]P.N3<.%XD-D($ 7F
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MB6 IYM;"23\1YPK1_\3.Z!,P')@DL&"$#P9ZCZ'=7*2R2BNOQ#++AQ K2"$
MK&*@! ]T<DFZD'#"*2WI6D- *@:B1&A*+36:2+>+[)P3(0;DY*T@"BCX (+Y
M?LRN+I1NFHLD,A55T[,SE^HQ._ZX@8$-'&@R2CV0G#OJNC9;U&V@*RBMCTRC
M)B!@ LQ".VZ^- W]PK*VRFP-)$<]BS2"&[J!P0H)HLHASSNK4HPQ!M@(H308
M+K!0.0)ZM*Q(,F]==*3["+SI. @Z"&$>':!9*QP!;Q"7.O32&B%8W!CR$L_=
M#J(H3!Q&&+<UG>ZK+%6GR*4).R#_I>ZF B+%3ZD'1O IA-JNT.H!IS2+M?^
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ME!:7&!@$/#MTVB8I((W;JH=$^  VJ(#P&YPQ.KX608PID9.^/$B(X#$^VRH
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M@*_I( Y:O!ZYOAI2LJ9 BN:2K,P8&-0Q)T;+0;0TJB)CO&KTH1O(1H880\R
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M_"D/0A0&&PE*4&$(8>=6#/*!*,I+1U.,5.> $S&0[ >5*;PI3G.*FC"^1H4
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M0%S/Q[F=H(3=4;"!_,R133S>CT#&60S6U6CD2AFF0:K%)^6(/V GT9!DFWI
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M8-/IC<(;$7BXF#+A%!0K+O7KIT9U@@3]7JM9 5LV;-BSY;5N?>0;0X5'KR"
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M(BZW@RQ"4 378 3RB"8Z3KXJ!S CH#+^[CK(YRC@R,)VT.=N( <7+Q0!( C
MC;?(:"LX)1AGCY^$* 5,X)/@<960#!Y!;\B0\'?FT5A^!P1.P"+J<F9D8A;3
M*RJ0Z"L@H&SRY#6M_W1=H*,O'M U?:,G2D"H$F.C+,L_4.;!8("]1"KC$D<2
M$\,_591$YNQ"P^<H\*PC0D*WP$I1HJHCMF_P--"[*F<F&\4!+BLL7"KA%NK\
MS&@\H<IT)NHHX*>FON_0C",DBDU+L^9"'K&LXF(D+F8WH0(KHV=H/L,9,4U
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M,5=BRS\49ZI&8[0 P X^:7<^\]T4MW&5\+ Z;P7T +("6XIRL'4QB?5@9("
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M1 E*FMVQPA%'4S@%^'>#!'4^QX (%J@E\GL&82 <P"PN-IY#]M*%\5S>O*4
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MI5,"3L,2.V>GX,@G4TIC9K0E9:D=X)%M?!(<;B2%]M%Q0W:$._(>@"DG"(0
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MAP_H +((NBK[P-72+K+ D0Q<M 7(1-6ZPVD*#7ZP@F[PP*20D[1@B'P"KXT
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M#@0%/@.##"(P@3J0CR[(!P[H!PZ0T0F[/N>CL'<]*0,ID.FCT1RJO@K;  X
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M /\;<J"2; 64/I_=K!"?&1%Z3N1-.:B RCY@W ]HX+C&K6T:^N>7!NXN(D3
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MS1% 2BG&>?"&1"I$?A'F<OY%A.@,B02)CE@'&]!'C]Z8?J9JL1KKL2+KF#(
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M30S0[!8(3Q;#3T*BPV)/(31C?Z $4+JM>FP.9GJE9_KC:_2@.^S-?18"04!
MDHBL$U="8N*-F#PET;Z$9NQ@0U*1#NQ$-##QLZPQ-$)N]IS+Y%X1_#A&0'I&
M;5!CIRZ!]8#ETW;*5S9D'($BHC8JTCJ0%D\2)5-R)L:*C7ZN&SI Q/R%Z49$
MBE@LL,+)'TH$ 8Z/BGI2&?]J <9) NI!GRZ#&UV/)<;Q_R$&,;CXZ2+R#]0J
M1@PQ93',9GKDT-P8;"%XPVB40XTT\C.,K+]6H"/:2JFFP+LZ 1YYYB3LX* *
M@Y%<HC"F!,E*4I=2AHWL9#:,BT^^9-XNX5:<J[X6Z*)$C[]6PCU H"^) R,*
M@CJ&258PH@@XH!8\(JJ"Q;.HH(/DZ()PBK=$125#4S1'DR940[3 A% 8  ?*
M!0:LH*^X"2H"JT0:2YN.#W>@;XI8C FASQ^VP@/28#B,*5<4J"7HTLK6,"4B
M!A^_#]-<A9BPT!OM0#UD[XPZR>]B8RH9 \[,)N1$(I=FPVI.XVA(0#.Z8,[
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AW=5?'=9C7=9GG=9KW=9O'==S7==WG==[W==_/7 " @ [

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140714724828320">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover Page Cover Page<br></strong></div></th>
<th class="th"><div>Nov. 01, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Nov.  01,  2023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">SANGAMO THERAPEUTICS, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-30171<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">68-0359556<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">7000 Marina Blvd.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Brisbane<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94005<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">510<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">970-6000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.01 par value per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">SGMO<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001001233<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>sgmo-20231101_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="sgmo-20231101.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
        </entity>
        <period>
            <startDate>2023-11-01</startDate>
            <endDate>2023-11-01</endDate>
        </period>
    </context>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-21">2023-11-01</dei:DocumentPeriodEndDate>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-22">0001001233</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c-1" id="f-23">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="c-1" id="f-1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-2">2023-11-01</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c-1" id="f-3">SANGAMO THERAPEUTICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-4">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">000-30171</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-6">68-0359556</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-7">7000 Marina Blvd.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-8">Brisbane</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-9">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-10">94005</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-11">510</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-12">970-6000</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="c-1" id="f-13">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c-1" id="f-14">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c-1" id="f-15">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c-1" id="f-16">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="c-1" id="f-17">Common Stock, $0.01 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-18">SGMO</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-19">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-20">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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MI=\'N#>_!XP,WZ(5%7 1.'52JQ$:A]/[\"^,Z>CT?Y;1#U.FEC9*CZ!@5M9
M,BHJI[9&L"[=@M+G ]RF0U@$<;X0'A*ZK$3!!6I12J</<),^1&D , HL?P0+
M\HU\9-7QP:7 ZGWX"QJ59W_WZ'YI[^IP'H)IT21A"U#SKCI@VVI__=U7C,SR
M*^=<&KC YL45H^ 7M@&\7TAIWBOV%EO\"-'_'U!+ P04    " !3@&%7GZ ;
M\+$"  #B#   #0   'AL+W-T>6QE<RYX;6S=5VUKVS 0_BM"/V!N8FKBD1BV
M0&&PC4+S85^56'8$>O%DN7/ZZZ>S;"=I=67=A['-H<G=/;J[1W<GF:Y;=Y+\
MX<BY([V2NMW0HW/-^R1I#T>N6/O.-%Q[I#)6,>=56R=M8SDK6W!2,EG>W&2)
M8D+38JT[=:=<2PZFTVY#;VA2K"NCSY:4!H-?RA0GCTQNZ)9)L;=B6,N4D*=@
M7H+A8*2QQ'DJ?$,78&F? KP(&K <XRBAC05C$C*$[_VX_!DP::U7A90SP24-
MAF+=,.>XU7=>&18/QA<0&>7=J?$,:\M.B^4M/3L,/S[)WMB2VSG-@DZF8BUY
M!72LJ(_PZTR3 .B<45XH!:N-9@.'R6,4?-@#E_(!6OBMNHK=5R3TXE,);2"P
MU4GTA$8QA D*Q+^,%F)?A+W]K;"D$8_&?>S\;O2@?^^,X_>65Z(?]+Z:\V/1
M%WATUC3R]$&*6BL>]O[+"8LUF_S(T5CQY+/!I!R\@5M*'KEUXG!I^6%9L^.]
MFZ:IKW#.RW^0\Y^M<\TUMTQ>DO:C_S=7^2V,D_'T7!S1JP,Z6PE<A!OZ%>Y7
M>>9 ]IV03NA1.XJRY/K%.?7A'=O["_PJOE]?\HIUTNUF<$//\A=>BD[E\ZI[
MJ,NXZBQ_AOMHD<VWL,\E=,E[7FY'U=;[021>\%G'!QR>(W?#$T<PGX#%$<"P
M/!@#S"=X87G^I_VLT/T$#..VBB(KU&>%^@2O&+(=/EB>N$_NG_A.\SQ-LPRK
MZ'8;9;#%ZI9E\!>/AG$##RP/9'I;K?%NXQ/R^AQ@/7UM0K"=XI.([12O-2#Q
MNH%'GL>[C>4!#ZP+V.Q _G@>F*FX3YI"5S%NV G&D3S'$)C%^(QF&5*=##[Q
M_F"G)$WS/(X %F>0IA@"IQ%', ;  4/2='@//GL?)=-[*CG_5U/\!%!+ P04
M    " !3@&%7EXJ[',     3 @  "P   %]R96QS+RYR96QSG9*Y;L,P#$!_
MQ=">, ?0(8@S9?$6!/D!5J(/V!(%BD6=OZ_:I7&0"QEY/3P2W!YI0.TXI+:+
MJ1C]$%)I6M6X 4BV)8]ISI%"KM0L'C6'TD!$VV-#L%HL/D N&6:WO606IW.D
M5XA<UYVE/=LO3T%O@*\Z3'%":4A+,P[PS=)_,O?S##5%Y4HCE5L:>-/E_G;@
M2=&A(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/
M['X 4$L#!!0    ( %. 85?E:(KL.0$  #("   /    >&PO=V]R:V)O;VLN
M>&ULC5'1;L(P#/R5*A^PEFE#&J*\@+8A31L:$^^A=:E%$E>."QM?/[=5!=)>
M]F3[;%WN+O,S\7%/=$R^O0LQ-[5(,TO36-3@;;RC!H)N*F)O14<^I+%AL&6L
M <2[]#[+IJFW&,QB/G)M.+T=2* 0I*!@!^P0SO&Z[\;DA!'WZ%!^<M/W#DSB
M,:#'"Y2YR4P2:SJ_$N.%@EBW+9B<R\UD6.R !8L_\+83^67WL4?$[C^M"LG-
M-%/""CE*?]'S6]5X CT>IE;H&9T KZS "U/;8#AT-.HBO;'1YS#6(<09_R=&
MJBHL8$5%ZR'(D".#ZP2&6&,331*LA]PLZ02<;.P!DFO;^=,'U^7@553D37(\
M0UWPNASDCAI+J#! ^:ZT47'-J]APTI6>Y_[A<?*DN;3.+17["&]DR]'R^%V+
M7U!+ P04    " !3@&%7)!Z;HJT   #X 0  &@   'AL+U]R96QS+W=O<FMB
M;V]K+GAM;"YR96QSM9$]#H,P#(6O$N4 -5"I0P5,75@K+A %\R,2$L6N"K<O
MA0&0.G1ALIXM?^_)3I]H%'=NH+;S)$9K!LIDR^SO *1;M(HNSN,P3VH7K.)9
MA@:\TKUJ$)(HND'8,V2>[IFBG#S^0W1UW6E\./VR./ /,+Q=Z*E%9"E*%1KD
M3,)HMC;!4N++3):BJ#(9BBJ6<%H@XLD@;6E6?;!/3K3G>1<W]T6NS>,)KM\,
M<'AT_@%02P,$%     @ 4X!A5V60>9(9 0  SP,  !,   !;0V]N=&5N=%]4
M>7!E<UTN>&ULK9--3L,P$(6O$F5;)2XL6*"F&V +77 !8T\:J_Z39UK2VS-.
MVDJ@$A6%3:QXWKS/GI>LWH\1L.B=]=B4'5%\% )5!TYB'2)XKK0A.4G\FK8B
M2K636Q#WR^6#4,$3>*HH>Y3KU3.T<F^I>.EY&TWP39G 8ED\C<+,:DH9HS5*
M$M?%P>L?E.I$J+EST&!G(BY84(JKA%SY'7#J>SM 2D9#L9&)7J5CE>BM0#I:
MP'K:XLH90]L:!3JHO>.6&F,"J;$#(&?KT70Q32:>,(S/N]G\P68*R,I-"A$Y
ML01_QYTCR=U59"-(9*:O>"&R]>S[04Y;@[Z1S>/]#&DWY(%B6.;/^'O&%_\;
MSO$1PNZ_/[&\UDX:?^:+X3]>?P%02P$"% ,4    " !3@&%7!T%-8H$   "Q
M    $               @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0
M   ( %. 85=:;NI"[0   "L"   1              "  :\   !D;V-0<F]P
M<R]C;W)E+GAM;%!+ 0(4 Q0    ( %. 85>97)PC$ 8  )PG   3
M      "  <L!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ 4X!A
M5\\I"G!5!   D!   !@              ("!# @  'AL+W=O<FMS:&5E=',O
M<VAE970Q+GAM;%!+ 0(4 Q0    ( %. 85>?H!OPL0(  .(,   -
M      "  9<,  !X;"]S='EL97,N>&UL4$L! A0#%     @ 4X!A5Y>*NQS
M    $P(   L              ( !<P\  %]R96QS+RYR96QS4$L! A0#%
M  @ 4X!A5^5HBNPY 0  ,@(   \              ( !7!   'AL+W=O<FMB
M;V]K+GAM;%!+ 0(4 Q0    ( %. 85<D'INBK0   /@!   :
M  "  <(1  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    (
M %. 85=ED'F2&0$  ,\#   3              "  :<2  !;0V]N=&5N=%]4
?>7!E<UTN>&UL4$L%!@     )  D /@(  /$3      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="sgmo-20231101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/CoverPageCoverPage</Role>
      <ShortName>Cover Page Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="sgmo-20231101.htm">sgmo-20231101.htm</File>
    <File>sgmo-20231101.xsd</File>
    <File>sgmo-20231101_lab.xml</File>
    <File>sgmo-20231101_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "sgmo-20231101.htm": {
   "nsprefix": "sgmo",
   "nsuri": "http://www.sangamo.com/20231101",
   "dts": {
    "inline": {
     "local": [
      "sgmo-20231101.htm"
     ]
    },
    "schema": {
     "local": [
      "sgmo-20231101.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "sgmo-20231101_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "sgmo-20231101_pre.xml"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 3,
    "http://xbrl.sec.gov/dei/2023": 3
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 23,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 23
   },
   "report": {
    "R1": {
     "role": "http://www.sangamo.com/role/CoverPageCoverPage",
     "longName": "0000001 - Document - Cover Page Cover Page",
     "shortName": "Cover Page Cover Page",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20231101.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20231101.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.sangamo.com/role/CoverPageCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.sangamo.com/role/CoverPageCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.sangamo.com/role/CoverPageCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.sangamo.com/role/CoverPageCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.sangamo.com/role/CoverPageCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.sangamo.com/role/CoverPageCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.sangamo.com/role/CoverPageCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Soliciting Material",
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.sangamo.com/role/CoverPageCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.sangamo.com/role/CoverPageCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.sangamo.com/role/CoverPageCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.sangamo.com/role/CoverPageCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover page.",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.sangamo.com/role/CoverPageCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.sangamo.com/role/CoverPageCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.sangamo.com/role/CoverPageCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.sangamo.com/role/CoverPageCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Tender Offer",
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.sangamo.com/role/CoverPageCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.sangamo.com/role/CoverPageCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Issuer Tender Offer",
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.sangamo.com/role/CoverPageCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.sangamo.com/role/CoverPageCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.sangamo.com/role/CoverPageCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.sangamo.com/role/CoverPageCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Written Communications",
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.sangamo.com/role/CoverPageCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001628280-23-035948-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-23-035948-xbrl.zip
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M<"+S?-T\9MU29L:81]LZ =+"Y'TE<M-NVA2E/S%S5\J7A0+6;!Y;5\(?B%$
MW$&W+A/01[#5Y[Y3M]Y=".#77\0@Z^K3EZ^_@!&?"RTC$UO:H,' 7M1>[3D
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M%\D2XO8EK@R7,0';N93X,?$Q9JXD!,<A"N7 >#0C/47INCJY:'6M,A5_O/D
M@P2+' 9;K5I DI60+)/M4@4#K1RBT>ML[!%=.9%>,,8XDE=I@A"C%W"!F%L$
MV 6!7#2BV!#BJ%'ZALZXQH"XX$G"W_(:W;2R3<_E&\$<7&%HVM86@VT,6@DL
MOR% WIL6S!#!62=48[T\FD?8&*5FZ9HXJ_CA;)?02?=O0^D)O_;%.97A" L
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MMQMN<%G5$!B*U\@*1WE\]Q67H/9#80@ETWL;B=X\2_U=>BEC.AD1T3W3[D0
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M_G'.E2#W,KRQ$\!BMSSA=ET$&@T48C9JG'L$73*0%/0%'((7!7<"HIV0C%)
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M8V[EDL1ENO2EMR]KGN8\*,@?,!4?:SF)ZE:W&$*.Q-3$D*9X"[[2YAW3%%D
MPQYH=3I8;RHVOFU1Q#FSF3X7JZ^,EFGAPGC!F>W3BT#<W:C,Q/S+NJ7X/!TL
M+I3H2$?GC')%V?CQV0^./*T3H#]GJ&P$K5=G)S9(JL=)&]YD'81%==<M=GT?
M>7-)+Z!J?029MIJ-VG^EV\)H1QA'>7,[6.FL MKF3=Q@U<5V=>$5#'V^Z7^E
M3=]YQ !OV8&IY -DFAY.*]7)N9DR [,ZJILT*@7%(G'!_^9;K%L?E\N87MLP
M$HD+B?D4(K)M)%RIM[K2"V@9>92WDE?08\R#@K*Y"9L8O4V(DF@01J MT7MG
M'" $MI5&F+RC%YP/J#<IER=N=V_]*SW"(MN ^@4"+PRD=LZ !CFI)X'/'$/J
MFX'WN5V'%-VP! D']S/2WTD$D2BTX]LDUU?L#ILY[".Z>P\6Y2SOO;=T\=92
M5J8E0YS?04X:D4XJ(]6(V8]SDI2>BI0K.:4RD&2@B3Y%^N9UA9>15E$5G9ST
MA_1GD[F-=-I)9_N%!P%W]K<,!,#P, '/)EAO[]=8A%E,5-!GF6 VE7_2"18:
M]8Q-,?)@FY<4;B!0_6F.C'$(YC R!MHX&B(JG0B@.;_&[KN>Y!PNU_+E#JDQ
M+Q!ST!]/,*J+(.10&#11\G3)W(J)%)/Y1 SJ@JER\$M<XQAAQ0%OJ<SE>PN.
MM(BA4I_ '469QJ16M#C[1Q=I3"ORF@@G\LC]9B)@2<#]29H?R"]@YQ)L,TEZ
M%AH5!;RL,).-R[V,W#:'ON#T$2FLU!GD* J]1K64<4<N"$X.JABS?U3[2OE"
M:C:DMW0#O+:P",[>J54DB])W8#JXT)FJ%:45X4.C,*S.!8UA3\:JF<M,T!)7
M:E#U=O"9B>?TWB;MS. 1M8H94;>H,W-N96E(^^!GSWZ8"4(2)^:*[?E_2S%*
MWBC@XNY]8MM[XA.^E=O3>2D]C:M_?ML^/-:UA^<^0A\$NJ68R9L/GX-$@<7\
M4WDW2BZC^F/]6Y(YJ_#GM_N=XWR!5DE&1M[E[L&ML8&ED&)[[FG4T(;5JJSC
M@[..*[FZ';.]N*#VZNSSV<GUV:EU\O7BZNOG\],N_O+Q_*)[<7+>_6S![]V2
MZ-B[Q!>)J]*U<PI]@P2:="/;1*EC+'@84MY"Q.*71W2J^API(]!TI"8E4\:1
M?&]^.#9'["N?)D ?'6O!T%J 0C9[HB9*"C_.Y*_>8!G4ER7HGO7C.CV:.1Z4
MGW6.ZD>M]M+'C7ISZ;-5S38;];VCO7LUN_K97GMYI]5@2SC8_49KK6;ON.IC
MP[N]GNF^E#DSJ:_WTKDW#%*^9JG74UX+/IP[L'?%?)=>-?,Z7UU32I8V?[2.
M0+'_?1Z1.EQ+HJZ'H936%WAO&%EGF&]&OU-(.3^&3.TH=2ZPNG=]XCQ4AG)'
MN2\[*[LQ?UQVN4E8.,GB@1-^;81K/:XY?U&TJ83J483JF:Y*W^HM<Y>X S^9
MO^[LKCF^^ALN=O@2BR.[??2P.[]V_]Z62G!W4'!;^W9GOU%);B6YNR:YS8..
MW3RJ1+<2W9T3W<..W=@_*IWD;@S.%U^07&IP_G71)KJU$IGWOTR[:J,\;3SJ
M1=RM>FNOY/)^N63SV%*!7W7S^P):K'_S^_;,[=Z!W3B\I[DM"QQXR?S9W[.;
MS?V*/V7E3_.P;;?WFA6#RLR@@^:V+-PCP<:=<:F?I"_-O8G"'2E?T<D8:B+O
MY5074&,G9*YM'S4W37FNX/R3V(1UT>1+Y,^^W6I7_"DM?SJ'=F._XD]Y^8/Z
MLZE+?2S^O+8H]7SQ'6M\SM==&XE>4RA+V^-:L_L3*BA>,:ABT)JY]R.[<[A7
M\:>L_-FN KVV6/9\]86CKRF@[73L@Z-M ;X*D#^18:@8])QI_%:[5?&GK/S9
MK@(]9DC;ZI3?LUXO.0S[(='J VI^2B:+S>:>?=BXYYI?^8NW7B=3#YMV>Z]3
M\?0E\;1]N&\WVY6BOBBFMEI']M%>^?8KO(8"Q,]X(BW?]I-NJ'Y(F/URI/)=
ML[%O=QJ'OVR*34M@9AXQK'A!#-WKV(='G8J?+X6?K6;3/NKL5PQ]*0QM=B ,
M.SPJ$T-?PP[A<W,S278$MO*=8"1MRY>OJC2[;>\UJ\6XTK*G:1_<=Y]2Q9[G
MV'6^W[SG!LB*/<^P[\0^N&\ZK JEUPVE>[(?T!78Z#^M6/RX9XK]!8*[1@O"
MKW:9P%V%UA\43K?M9FNOXN=+X6<+%+3=KL+I%\/09J=A-]NETM#7$4X;WY]>
MJ?&N)WW95_$<*UXRWFS:K8,J'"@M>]H5;TK+FW<=^[#16-]P5ZQYQG.>MJ4W
MKR&&OI"QY4$<_320Y44=/[79S$NL4>^:C8[=W'^)F8%*;%^PV&+^8Z]4T54E
MM974WFELCP[LO1>9Y:G$]B6+;:=AMQNELK:/>BI"8X' T>]XX( ?OZ\=C<N%
MU'\7D7+X&#^%=\BY6"M"V#V[_NL!M;QM((P;)'BLPOU5=*L$>LA!LBMG?Z>,
M;G7:[_ >K8TS%VO.?7T]36GPF'F-2GY?A?RV-Z@1KN2WDM]23?M=L]ZLY+>2
MWYV5WT9]DR*AYY'?1SV'9>>@_A5B^<A*(CKN# @P&B>TB;RW1@Q@/:3\[7Z+
M0ULE5O/@P&X>;'HZ\0IY>2I;^X@U,[O(IKU#N]%YUN-!*C;=1YO:=OM@TRT9
M%9N>79L:]N'>I@OCC\@F<M"_TD7O'[+[XDW7^NIW2@*VB"\[<X_\0:=^<'#P
MZF\[WSLZW,)MY\^1[UY\4^GOPA.^(ZVKH01$5=(+SG?A:OG9BV&7G46UR'!M
M-J?R77=;O*J[%ZY[<? ]Y&(GZ'$J'4V.IB''5JX#WMXRVHF(AK;EP+^6_"M1
M$^$!DR*;0CCP:S=2^T7I)*&*U=8O#=[9!,R#EEFW"^7:+;O9O.?M.H^]VKKM
M+&(EPSLIP^W&@=TY."BC##]3$>_V7 P?-+GXO.8'1[X[K%^+IEAN+6HUC^S]
MHTVUJ'RYETKJ=DGJ]O9;]E[C60\^?Z"%WK4@@"UT% ?.S3#PP-=%=!3SP3'%
M!/'T(1M;7IK^+)IBN?6GV>[81ZU-%S8>M$=I*RB]DKHRS:UUU+G_$:[/N@#0
MZBQ*4ST_V5I(MK=OWZ;$FAVS?K'3JA_@(L,XB!2>SOH^E![=[IFM+6#V._>A
M7IEH9)^('D0Q2;S\DV7T^(!ILN(("__V G<*_QG&(^_#_P%02P,$%     @
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MX<L/5+M?IKV]A+?[3;&]++^,;1)$'%MO:]+YES':"__G,ZLLORITF:!!%O4
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M2P$"% ,4    " !3@&%7L[FM!C8R  !GR0$ %0              @ $
M97AH:6)I="TY.3$Q,3 Q,C,N:'1M4$L! A0#%     @ 4X!A5WT'0'H)$
M5X8  !$              ( !:3(  '-G;6\M,C R,S$Q,#$N:'1M4$L! A0#
M%     @ 4X!A5TR5KHMS @  EP<  !$              ( !H4(  '-G;6\M
M,C R,S$Q,#$N>'-D4$L! A0#%     @ 4X!A5RL!9%MZ"@  1EX  !4
M         ( !0T4  '-G;6\M,C R,S$Q,#%?;&%B+GAM;%!+ 0(4 Q0    (
M %. 85=13>8[L@8   ,Q   5              "  ?!/  !S9VUO+3(P,C,Q
A,3 Q7W!R92YX;6Q02P4&      4 !0!' 0  U58

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
